1 week Ago By Defense World Staff
Raymond James Financial Inc. bought a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC.
The firm bought 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. A number of other hedge funds and other institutional investors have also modified their holdings of RCKT. KBC Group NV increased its position in Rocket Pharmaceuticals by 159.
6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 3,366 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Rocket Pharmaceuticals in the 4th quarter valued at approximately $141,000.
Private Advisor Group LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth approximately $166,000. XTX Topco Ltd purchased a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at approximately $286,000. Finally, Verition Fund Management LLC acquired a new position in Rocket Pharmaceuticals in the third quarter valued at approximately $290,000.
98.39% of the stock is owned by institutional investors and hedge funds. Rocket Pharmaceuticals Price PerformanceRocket Pharmaceuticals stock opened at $4.
94 on Friday. The company has a quick ratio of 6.05, a current ratio of 6.
05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals, Inc.
has a 52-week low of $4.55 and a 52-week high of $26.98.
The firm has a market cap of $526.75 million, a PE ratio of -1.80 and a beta of 1.
00. The company’s 50 day moving average is $8.50 and its two-hundred day moving average is $12.
18. Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.
62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06.
On average, research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.
Insider ActivityIn other Rocket Pharmaceuticals news, insider Kinnari Patel acquired 21,099 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $4.70 per share, for a total transaction of $99,165.
30. Following the acquisition, the insider now owns 26,774 shares in the company, valued at $125,837.80.
The trade was a 371.79 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Also, CFO Aaron Ondrey sold 7,489 shares of the firm’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.
81. Following the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50.
This trade represents a 5.46 % decrease in their position. The disclosure for this sale can be found here.
Company insiders own 28.50% of the company’s stock. Wall Street Analysts Forecast GrowthSeveral research firms have issued reports on RCKT.
Wedbush assumed coverage on Rocket Pharmaceuticals in a research note on Monday, December 30th. They set an “outperform” rating and a $32.00 target price for the company.
Scotiabank raised their price objective on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd.
The Goldman Sachs Group decreased their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd.
Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company.
Finally, Canaccord Genuity Group decreased their price objective on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a report on Monday, March 3rd.
One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Rocket Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $43.
00.View Our Latest Stock Analysis on Rocket PharmaceuticalsRocket Pharmaceuticals Company Profile (Free Report)Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read MoreFive stocks we like better than Rocket PharmaceuticalsWhat is Short Interest? How to Use ItJoby Aviation: Operational Momentum vs. Market SentimentWhy Are These Companies Considered Blue Chips?Broadcom’s Big Outperformance Shows Strength Amid Tariff DeclineHow to find penny stocks to invest and trade Carvana: Can Turnaround Strength Outdrive Market Headwinds?.
